Tomer Wasserman

Articles by Tomer Wasserman

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Giuliano Borges,Rinat Yerushalmi,Marina N. Sharifi,Wassim McHayleh,J. Thaddeus Beck,Neelima Vidula, MD,Erika P. Hamilton, MD,Kristine J. Rinn,Joyce O’Shaughnessy, MD,Giuseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Giulia Tonini,Alessandro Paoli,Monica Binaschi,Li Cheng,Jennifer Crozier,Tomer Wasserman,Virginia Kaklamani, MD, DSc

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce O’Shaughnessy, MD,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Giuseppe Curigliano,Hope S. Rugo, MD,Carlos H. Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Tomer Wasserman,Sara M. Tolaney, MD, MPH

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Cristina Saavedra,Vicente Carañana,Isabel Blancas,Carmen Hinojo-González,Alfonso Cortes-Salgado,Elena Galve,Rui Rui Zhang,Miguel Sampayo-Cordero,Daniel Alcalá-López,Juliana Carvalho-Santos,Olga Boix,Ana Garrido,Carlos H Barrios,Giuseppe Curigliano,Rupert Bartsch,Anne Claire Hardy Bessard,Tomer Wasserman,Javier Cortés, MD

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce A. O’Shaughnessy,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Guiseppe Curigliano,Hope S. Rugo, MD,Carlos Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Leo Viana Nicacio,Tomer Wasserman,Sara M. Tolaney, MD, MPH

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Rui Rui Zhang,Miguel Sampayo-Cordero,Juliana Carvalho-Santos,Olga Boix,Marta Beltran,Carlos Barrios,Guiseppe Curigliano,Rupert Bartsch,Anne Clair Hardy Bessard,Anna Compagnoni,Kathy Puyana Theall,Thomas Buechele,Tomer Wasserman,Javier Cortés, MD

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Marina Sharifi,Kristine Rinn,Wassim McHayleh,Rinat Yerushalmi,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Bartomeu Piza Vallespir,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Erika P. Hamilton, MD,Eva Ciruelos,Ji-Yeon Kim,Elena López-Miranda,Elia Seguí,Neelima Vidula, MD,Joyce O’Shaughnessy, MD,Guiseppe Curigliano,Javier Cortés, MD,Alessandro Di Sanzo,Paula Muñoz Romero,Bartomeu Piza Vallespir,Manuel Dominguez,Kathy Puyana Theall,Alessandro Paoli,Monica Binaschi,Tomer Wasserman,Virginia Kaklamani, MD, DSc

Latest Updated Articles